陕西中医2025，Vol.46Issue(11)：1504-1508,5.DOI:10.3969/j.issn.1000-7369.2025.11.011
葶苈生脉五苓散联合沙库巴曲缬沙坦治疗射血分数降低心力衰竭疗效研究
Study on efficacy of Tingli Shengmai Wuling San combined with sacubitril/valsartan in treatment of heart failure with reduced ejection fraction
摘要
Abstract
Objective:To investigate therapeutic efficacy of Tingli Shengmai Wuling San combined with sacubi-tril/valsartan in patients with heart failure with reduced ejection fraction(HFrEF)and its effects on myocardial fi-brosis markers[serum N-terminal pro-brain natriuretic peptide(NT-proBNP),soluble growth stimulation expressed gene 2 protein(sST2),tissue inhibitor of matrix metalloproteinase(TIMP-1),and matrix metalloproteinase(MMP)-9].Methods:A total of 120 HFrEF patients were randomly divided into two groups(n=60 each)using a random num-ber table.Tingli Shengmai Wuling San group treated with Tingli Shengmai Wuling San and sacubitril/valsartan,the valsartan group treated with sacubitril/valsartan alone.Clinical efficacy,cardiac function indicators,6-minute walking distance(6MWD),traditional Chinese medicine(TCM)syndrome scores,myocardial fibrosis markers,and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate in the Tingli Shengmai Wuling San group was 95.00％,significantly higher than 83.33％in the valsartan group(P＜0.05).Left ventricular ejection fraction(LVEF)increased in both groups,with greater increase in the Tingli Shengmai Wuling San group(P＜0.05).Left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)decreased in both groups,with greater reductions in the Tingli Shengmai Wuling San group(all P＜0.05).TCM syndrome total scores decreased in both groups,with a lower score in the Tingli Shengmai Wuling San group(P＜0.05).The 6MWD increased in both groups,with a greater improvement in the Tingli Shengmai Wuling San group(all P＜0.05).NT-proBNP,sST2,TIMP-1,and MMP-9 levels decreased in both groups,with lower levels in the Tingli Shengmai Wuling San group(all P＜0.05).Additionally,tumor necrosis factor-α and IL-6 levels de-creased in both groups,with lower levels in the Tingli Shengmai Wuling San group(all P＜0.05).Conclusion:Tingli Shengmai Wuling San combined with sacubitril/valsartan can slow ventricular remodeling,improve cardiac function in HFrEF patients,and demonstrate superior therapeutic efficacy.关键词
射血分数降低心力衰竭/葶苈生脉五苓散/沙库巴曲缬沙坦/氨基末端脑钠肽前体/可溶性生长刺激表达基因2蛋白/基质金属蛋白酶组织抑制因子-1/基质金属蛋白酶-9Key words
Heart failure with reduced ejection fraction/Tingli Shengmai Wuling San/Sacubitril valsartan/N-terminal pro-brain natriuretic peptide/Soluble growth stimulation expressed gene 2/Tissue inhibitor of metal prote-ase-1/Matrix metalloproteinase-9分类
临床医学引用本文复制引用
许世强,苏莉莉,丁亚楠,高立威,梅命珠..葶苈生脉五苓散联合沙库巴曲缬沙坦治疗射血分数降低心力衰竭疗效研究[J].陕西中医,2025,46(11):1504-1508,5.基金项目
河北省中医药管理局科研计划项目(2022471) （2022471）
